HUTCHMED (NASDAQ:HCM) Shares Gap Down – Time to Sell?

HUTCHMED (China) Limited (NASDAQ:HCM)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $16.53, but opened at $15.69. HUTCHMED shares last traded at $15.48, with a volume of 25,271 shares changing hands.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Monday, November 18th.

HUTCHMED Trading Up 1.6 %

The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68. The firm has a 50-day simple moving average of $14.63 and a two-hundred day simple moving average of $16.60.

Hedge Funds Weigh In On HUTCHMED

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HCM. Public Employees Retirement System of Ohio acquired a new position in shares of HUTCHMED during the 3rd quarter worth $35,000. Barclays PLC increased its position in HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company’s stock worth $35,000 after buying an additional 2,255 shares during the last quarter. Blue Trust Inc. raised its holdings in HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock valued at $102,000 after buying an additional 3,532 shares in the last quarter. Summit Trail Advisors LLC lifted its position in shares of HUTCHMED by 14.4% in the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock worth $189,000 after buying an additional 1,647 shares during the last quarter. Finally, OLD Mission Capital LLC acquired a new position in shares of HUTCHMED during the 4th quarter valued at about $230,000. Institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.